GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.

GSK’s Price Performance, Valuation & Estimate Movement. GSK stock has risen 20.1% year to date compared with an increase of 4.0% for the industry. The stock has also outperformed the sector and ...

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 ...

GSK PLC GSK shares rose 1.78% to £13.72 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.42% to 9,061.49. GSK PLC ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

GSK PLC GSK shares advanced 1.39% to £13.91 Thursday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.85% to 9,138.37. GSK PLC ...

GSK is a #2 (Buy) on the Zacks Rank, with a VGM Score of B. It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 9.52; value investors should ...

Spark’s Take on GB:GSK Stock According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform. GlaxoSmithKline’s stock is supported by strong financial performance and strategic initiatives ...

Analysts are also bullish on the stock because of the notable performance of its specialty medicine segment, which is GSK plc’s (NYSE:GSK) largest business area.

For new and old investors, taking full advantage of the stock market and investing with confidence are ... which is more than double the S&P 500's performance over the same time frame. However, the ...